Next-generation immunotherapy for solid tumors: combination immunotherapy with crosstalk blockade of TGFβ and PD-1/PD-L1 is a research paper published in Expert Opinion on Investigational Drugs (2022). On theSindex it has a DataRank of 0.312. It has been cited 7 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.312
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NCI NIH HHS
Grant: R01 CA235667
NCI NIH HHS
Grant: U01 CA214195
NCI NIH HHS
Grant: P30 CA008748
NCI NIH HHS
Grant: R01 CA236615
National Institutes of Health
Grant: 5R01CA236615-02
Image-guided irreversible electroporation directed CAR T-cell delivery to solid tumors
National Institutes of Health
Grant: 5U01CA214195-04
The EDRN Mesothelioma Biomarker Discovery Laboratory
National Institutes of Health
Grant: 2P30CA008748-43
MOUSE GENETICS
National Institutes of Health
Grant: 5R01CA235667-02
A phase I/II combination immunotherapy clinical trial: mesothelin-targeted chimeric antigen receptor T cells and checkpoint blockade agent in pleural mesothelioma
FWCI
0.47
Citation Percentile
0.6%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals